Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director William D. Waddill Sells 4,000 Shares

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) Director William D. Waddill sold 4,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $54.25, for a total transaction of $217,000.00. Following the completion of the transaction, the director now directly owns 13,130 shares in the company, valued at $712,302.50. This represents a 23.35 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Protagonist Therapeutics Price Performance

PTGX traded down $0.40 on Friday, reaching $52.65. 3,695,675 shares of the company traded hands, compared to its average volume of 755,411. The stock's 50 day moving average price is $41.21 and its 200-day moving average price is $42.63. Protagonist Therapeutics, Inc. has a 52-week low of $24.22 and a 52-week high of $60.60. The company has a market cap of $3.23 billion, a price-to-earnings ratio of 19.79 and a beta of 2.34.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its quarterly earnings data on Friday, February 21st. The company reported $1.98 EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $2.07. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. The firm had revenue of $170.64 million for the quarter, compared to the consensus estimate of $56.65 million. As a group, equities research analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Remove Ads

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $54.00 price objective on shares of Protagonist Therapeutics in a research note on Monday, March 10th. BTIG Research set a $73.00 price objective on shares of Protagonist Therapeutics in a research note on Monday, March 3rd. StockNews.com downgraded shares of Protagonist Therapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday, December 10th. Wedbush reissued an "outperform" rating and issued a $70.00 target price on shares of Protagonist Therapeutics in a research report on Tuesday, March 11th. Finally, Truist Financial lifted their target price on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a "buy" rating in a research report on Tuesday, March 11th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $62.56.

Institutional Trading of Protagonist Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC acquired a new stake in Protagonist Therapeutics in the fourth quarter valued at approximately $38,000. GF Fund Management CO. LTD. acquired a new stake in Protagonist Therapeutics in the fourth quarter valued at approximately $48,000. Harvest Fund Management Co. Ltd acquired a new stake in Protagonist Therapeutics in the third quarter valued at approximately $69,000. Covestor Ltd lifted its stake in Protagonist Therapeutics by 5,200.0% in the fourth quarter. Covestor Ltd now owns 1,643 shares of the company's stock valued at $63,000 after acquiring an additional 1,612 shares during the last quarter. Finally, KBC Group NV lifted its stake in Protagonist Therapeutics by 54.4% in the fourth quarter. KBC Group NV now owns 2,093 shares of the company's stock valued at $81,000 after acquiring an additional 737 shares during the last quarter. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.